Unknown PHASE1 INTERVENTIONAL 2-arm NCT04871334

Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma

A Multi-center, Phase Ia/Ib, Open Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma

Sponsor: Shandong TheraWisdom Biopharma Co., Ltd.

Conditions Advanced Melanoma Advanced Urothelial Carcinoma

Interventions TWP-101

Updated 5 times since 2021 Last updated: Jul 20, 2021 Started: Feb 7, 2021 Primary completion: Oct 31, 2022 Completion: Dec 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced Melanoma and Advanced Urothelial Carcinoma and is currently ongoing. Shandong TheraWisdom Biopharma Co., Ltd. leads this study, which shows 5 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jun 2023 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Sep 2021 — Jun 2023 [monthly]

Recruiting PHASE1
Jun 2021 — Sep 2021 [monthly]

Recruiting PHASE1

First recorded

Feb 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shandong TheraWisdom Biopharma Co., Ltd.

Data source: Shandong TheraWisdom Biopharma Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China